×
Masimo Cash on Hand 2010-2024 | MASI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Masimo cash on hand for the quarter ending September 30, 2024 was
$0.130B
, a
14% decline
year-over-year.
Masimo cash on hand for 2023 was
$0.163B
, a
19.66% decline
from 2022.
Masimo cash on hand for 2022 was
$0.203B
, a
72.78% decline
from 2021.
Masimo cash on hand for 2021 was
$0.745B
, a
16.19% increase
from 2020.
View More
Masimo Cash on Hand 2010-2024 | MASI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Masimo cash on hand for 2023 was
$0.163B
, a
19.66% decline
from 2022.
Masimo cash on hand for 2022 was
$0.203B
, a
72.78% decline
from 2021.
Masimo cash on hand for 2021 was
$0.745B
, a
16.19% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Thermo Fisher Scientific (TMO)
$214.1B
Intuitive Surgical (ISRG)
$183.6B
Alcon (ALC)
$45.1B
IQVIA Holdings (IQV)
$40.2B
Edwards Lifesciences (EW)
$39.6B
IDEXX Laboratories (IDXX)
$34.7B
DexCom (DXCM)
$26.8B
Waters (WAT)
$23B
STERIS (STE)
$22.4B
SONOVA HOLDING (SONVY)
$21.9B
Hologic (HOLX)
$18.7B
Fresenius Medical Care AG KGaA (FMS)
$12.4B
Sysmex ADR (SSMXY)
$11.9B
Globus Medical (GMED)
$11.2B
Teleflex (TFX)
$9.4B
Penumbra (PEN)
$9B
Glaukos (GKOS)
$7.8B
PROCEPT BioRobotics (PRCT)
$5.1B
Integer Holdings (ITGR)
$4.5B
Inari Medical (NARI)
$3.1B
TransMedics (TMDX)
$2.9B
LivaNova (LIVN)
$2.8B
Veracyte (VCYT)
$2.8B
Nihon Kohden (NHNKY)
$2.5B
Tandem Diabetes Care (TNDM)
$2.2B
Elekta AB (EKTAY)
$2.2B
Integra LifeSciences Holdings (IART)
$2.1B
RxSight (RXST)
$2B
Alphatec Holdings (ATEC)
$1.3B
Artivion (AORT)
$1.2B